Niall Martin, Artios CEO
December 3, 2020 07:14 AM ESTUpdated 08:02 AM
Deals

Mer­ck KGaA bets big on DNA dam­age up­start, push­ing $30M up­front and hefty in­cen­tives for a Lyn­parza pi­o­neer

Jason Mast

Editor

The DNA dam­age spe­cial­ists over at Ar­tios Phar­ma have re­mained large­ly qui­et in the 2 1/2 years since their last fundraise, but what­ev­er they’ve been …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

A service from the Financial Times